VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

MERS-CoV-S rRBD vaccine
Vaccine Information
  • Vaccine Name: MERS-CoV-S rRBD vaccine
  • Target Pathogen: MERS-CoV
  • Target Disease: Middle East Respiratory Syndrome (MERS)
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: Recombinant ribosomal binding site of S1 subunit of S from MERS-COV.(Chen et al., 2017)
  • S from MERS-CoV gene engineering:
    • Type: Recombinant protein preparation
    • Description: baculovirus-insect cell sf9-derived recombinant MERS-CoV was used to express rRBD (Chen et al., 2017)
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: monoclonal antibody of MERS-CoV, which mapped to a wide range of regions on the spike (S) protein of the virus. In addition to mAbs with neutralizing epitopes located on the receptor-binding domain
Host Response

Baboon Response

  • Vaccination Protocol: 35 μg MERS-CoV rS combined with 150 μL Freund’s complete adjuvant (Sigma, St Louis, CA, USA) via subcutaneous immunization and boosted twice at 2-week intervals beginning three weeks after the initial immunization (Chen et al., 2017)
  • Immune Response: anti-S protein IgG response and neutralizing activity (Chen et al., 2017)
References
Chen et al., 2017: Chen Y, Lu S, Jia H, Deng Y, Zhou J, Huang B, Yu Y, Lan J, Wang W, Lou Y, Qin K, Tan W. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerging microbes & infections. 2017; 6(5); e37. [PubMed: 28536429].